Finance
US says former Humanigen chief scientific officer charged with insider trading
Published by Global Banking & Finance Review®
Posted on December 23, 2024
1 min readLast updated: January 27, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on December 23, 2024
1 min readLast updated: January 27, 2026
Ex-Humanigen CSO Dale Chappell charged with insider trading, avoiding $38M in losses by selling stocks with non-public info.
WASHINGTON (Reuters) - An indictment unsealed on Monday charged the former chief scientific officer of biopharmaceutical company Humanigen with engaging in an insider trading scheme involving the firm's stock, the U.S. Justice Department said.
Between June and August of 2021, Dale Chappell, 54, avoided more than $38 million in losses by selling millions of shares of Humanigen stock while in possession of material non-public information about Humanigen's application to the Food and Drug Administration for approval of a drug to treat COVID-19 called Lenzilumab, the Justice Department said.
(Reporting by Kanishka Singh in Washington; Editing by Chris Reese)
The article discusses insider trading charges against former Humanigen CSO Dale Chappell by the U.S. Justice Department.
Dale Chappell, former chief scientific officer of Humanigen, is charged with insider trading.
The charges are related to Humanigen's FDA application for the COVID-19 treatment drug Lenzilumab.
Explore more articles in the Finance category
